You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Archive for June, 2015

The obesity-stroke paradox: why do obese patients have milder strokes?

15 Jun, 15 | by Arun Krishnan, Web Editor

Over the weekend, the Sydney Morning Herald wrote of the ‘heavy cost’ of obesity to the Australian health system http://www.smh.com.au/nsw/the-heavy-cost-of-obesity-and-how-nsw-health-workers-are-responding-20150613-ghmxbu.html . The article featured a quote that “the new normal is to be overweight or obese”. The epidemic of obesity has presented major health challenges that are not just faced by the developed world but which are now increasingly also becoming part of the health dilemmas facing developing countries.

There are groups of obese patients however who do not seem to encounter the health problems that one might expect and these patients have been called the ‘obese well’ http://www.ncbi.nlm.nih.gov/pubmed/23491523 The reasons for why these people remain free of health problems remains unclear although a number of theories have been put forward including reduced inflammatory mediators in this group of patients. Accordingly, the possibility that anti-inflammatory drugs may improve outcomes such as glucose control and diabetes risk is an ongoing area of research.

In the current issue of JNNP, Kim and colleagues from Seoul have demonstrated that mild-moderate elevations of body mass index (BMI) are associated with reduced stroke severity http://jnnp.bmj.com/content/86/7/743.abstract . This backs up previous studies that have shown lower risk of mortality in obese patients who suffer haemorrhagic or ischaemic stroke. The importance of these observations is that it lays the foundation for further studies that may be able to address why this group is relatively protected from severe long-term disability. This will help in drilling down on the potential ways of improving outcomes in all stroke patients, regardless of BMI.

Amyotrophic lateral sclerosis: from Charcot to cutting edge molecular genetics

3 Jun, 15 | by Arun Krishnan, Web Editor

For most clinicians, having to tell a patient that they have motor neuron disease/amyotrophic lateral sclerosis (ALS) is a difficult and challenging dilemma. In the community, it is one of the few remaining conditions that are inseparably linked with severe physical disability resulting in loss of independence and eventually loss of life. On a more optimistic note, the pace of research in this field provides hope for a cure or at the least for treatments that may slow the progression of the condition.

ALS was first described by Jean-Martin Charcot, the father of modern Neurology and in the current issue of JNNP, Turner and Swash http://jnnp.bmj.com/content/86/6/667.abstract chart the historical journey that commenced with Charcot’s initial descriptions of the condition, which largely remain true and accurate to the present day. In addition, the authors have also managed to provide a state-of-the-art review of where we are at in terms of genetic contributions to this condition and provide a thorough analysis on the potential cause of ALS.

In addition to the obvious question of who is likely to develop ALS, they also touch on another intriguing question of whether there are individuals who are likely to never develop ALS.

In short, this is a highly recommended review.

Latest from JNNP

Latest from JNNP